



VOLUME FIFTY TWO

ANNUAL REPORTS IN MEDICINAL CHEMISTRY

Medicinal Chemistry Approaches to Tuberculosis and Trypanosomiasis

Volume Editor

KELLY CHIBALE

*Drug Discovery and Development Centre (H3D),
Department of Chemistry and Institute of Infectious Disease
and Molecular Medicine, University of Cape Town,
Rondebosch, South Africa*



ELSEVIER

**ACADEMIC PRESS**

An imprint of Elsevier

Contents

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xi</i>
1. Tuberculosis	1
Steven J. Berthel, Christopher B. Cooper, and Nader Fotouhi	
1. Introduction: Tuberculosis (TB) disease burden and growing resistance development	1
2. Cell wall disruption	3
3. Protein synthesis	6
4. Electron transport chain	10
5. Protein degradation	15
6. Other	19
7. Conclusion	21
References	21
Further reading	25
2. Antituberculosis agents: Beyond medicinal chemistry rules	27
Marco Pieroni	
1. Introduction	27
2. Tuberculosis drug discovery: An overview	29
3. Drug-likeness of antituberculosis agents	30
4. Non-antimicrobial host- and pathogen-directed therapies	44
5. Conclusion	55
References	57
3. Development of MmpL3 inhibitors for tuberculosis treatment	71
Giovanna Poce, Sara Consalvi, Giulia Venditti, Cristina Scarpecci, and Mariangela Biava	
1. Introduction	71
2. Identification of the soft-hit BM212	72
3. Hit expansion campaign	73
4. H2L campaign	82
5. Target identification	93

6. Conclusions	94
References	94
4. Inhibitors of enzymes in the electron transport chain of <i>Mycobacterium tuberculosis</i>	97
Andrew M. Thompson and William A. Denny	
1. Introduction	98
2. The electron transport chain (ETC)	99
3. Inhibitors of succinate dehydrogenase (SDH)	100
4. Inhibitors of NADH dehydrogenase (NDH)	100
5. Inhibitors of menaquinone biosynthesis enzymes	104
6. Inhibitors of the cytochrome <i>bc</i> ₁ -aa ₃ supercomplex	110
7. Inhibitors of cytochrome BD oxidase	115
8. Inhibitors of ATP synthase	115
9. Conclusions	123
References	123
5. Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance	131
Nicolas Willand, Marion Flipo, Baptiste Villemagne, Alain Baulard, and Benoit Deprez	
1. Introduction	132
2. Pro-drugs in TB treatment	133
3. Thioamide prodrugs as good candidates for boosting strategies	133
4. EthR as a validated target to boost the bioactivation of ethionamide	134
5. Biological assays used for hits identification	135
6. Target-based screenings	136
7. Target-guided synthesis	138
8. Fragment-based approach	139
9. Phenotypic-based screening	142
10. <i>In silico</i> screening	143
11. X-ray structures analysis	144
12. <i>In vivo</i> proof of concept	145
13. Limitations to the development of EthR inhibitors	146
14. Identification of new bioactivation pathways to revert resistance	147
15. Conclusions	148
References	148

6. Sustainable anti-trypanosomatid drugs: An aspirational goal for medicinal chemistry	153
Maria Laura Bolognesi	
1. Introduction	153
2. Aligning basic and translational researches toward a more sustainable antitrypanosomatid pipeline	157
3. Toward the assembly of a sustainable small library for phenotypic purposes	159
4. Using a food waste product for making more accessible drugs against neglected tropical diseases	165
5. Conclusions	172
References	172